The Canadian Encyclopedia — neutral, cited, updated
September 12, 2026Sources cited
Canadianwire.
Canada’s encyclopedia & explainer
Home›Business & Money›Biotech›Mydecine Innovations Group
Business & Money • Biotech

Mydecine Innovations Group

Mydecine Innovations Group was a biotechnology company focused on developing psychedelic-inspired therapeutics and related drug-delivery technologies for mental health and addiction disorders.

By Ethan Anderson| Reviewed by Olivia Bennett, Standards & Fact-Checking Lead| Updated September 12, 2026|2 min read| Fact-checked

Mydecine Innovations Group was a biotechnology company focused on developing psychedelic-inspired therapeutics and related drug-delivery technologies for mental health and addiction disorders. It operated in Canada and the United States and was known for research programs involving psilocybin, MDMA-like compounds, and other novel molecules. In February 2026, the company announced a name and symbol change to Noveris Health Sciences Inc.

Overview

Mydecine Innovations Group was a public biotechnology company that developed psychedelic-derived and psychedelic-inspired therapeutics. It positioned its work around mental health, addiction, and controlled drug-delivery systems.

Research and development

Public descriptions of the company highlighted a pipeline that included psilocybin-based candidates, MDMA-like compounds, and novel analogue molecules. The company also referenced work with academic and pharmaceutical partners, including the University of Alberta.

Corporate history

Mydecine was founded in 2020 and later operated with headquarters in Vancouver, British Columbia, while also listing a Denver, Colorado location. In 2026, the company announced a corporate rename to Noveris Health Sciences Inc.

Market presence

The company traded under ticker symbols including MYCO, MYCOF, and 0NFA. It was described in exchange and market sources as a biotech company focused on regulated medicines for mental health applications.

Key facts

  • Developed first- and second-generation psychedelic-inspired medicines and delivery systems.
  • Research focus included mental health conditions, nicotine addiction, and PTSD.
  • Described itself as an emerging biotech and life sciences company with an R&D pipeline.
  • Maintained operations in both Canada and the United States.
  • Announced name change to Noveris Health Sciences Inc. in February 2026.
🍁
Canadian context

Mydecine had a Canadian corporate base in Vancouver, British Columbia, and conducted research and development in Canada, including work associated with the University of Alberta.

Frequently asked questions

What was Mydecine Innovations Group?
It was a biotechnology company focused on psychedelic-inspired medicines and related technologies for mental health and addiction treatment.
What did Mydecine research?
Public sources described research into psilocybin-based candidates, MDMA-like entactogens, novel analogues, therapy protocols, and drug-delivery systems.
Where was Mydecine headquartered?
Its corporate information listed Vancouver, British Columbia, as the head office, and company profiles also listed Denver, Colorado, as a location.
When was Mydecine founded?
Public company profiles described it as founded in 2020.
Did Mydecine change its name?
Yes. In February 2026, it announced a name and symbol change to Noveris Health Sciences Inc.

References

  1. LinkedIn — https://www.linkedin.com/company/mydecine
    Supports: Company description, industry, founding year, headquarters, and business focus.
  2. Mydecine Innovations Group — https://mydecine.com/corporate-information
    Supports: Corporate address in Vancouver, British Columbia.
  3. Aquis Stock Exchange — https://www.aquis.eu/companies/MYIG
    Supports: Company description, withdrawn trading status, and business focus.
  4. Newsfile — https://www.newsfilecorp.com/release/282389/CSE-Bulletin-Name-and-Symbol-Change-Mydecine-Innovations-Group-Inc.-MYCO
    Supports: February 2026 name and symbol change to Noveris Health Sciences Inc.
  5. MarketScreener — https://www.marketscreener.com/news/mydecine-innovations-group-inc-reports-earnings-results-for-the-third-quarter-and-nine-months-ended-ce7d5edbdf80f124
    Supports: Canadian biotech description, therapeutic focus, and research activity in Canada.